Zoetis Inc. (NYSE:ZTS) Receives $152.91 Consensus Target Price from Analysts

Zoetis Inc. (NYSE:ZTS) has earned an average recommendation of “Hold” from the thirteen research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $152.4545.

Several analysts have weighed in on the company. Barclays initiated coverage on Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. Stifel Nicolaus dropped their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. BTIG Research reissued a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Wednesday, December 3rd. Bank of America lowered shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price for the company. in a report on Monday, December 15th. Finally, HSBC set a $140.00 target price on Zoetis in a research note on Wednesday, December 10th.

Institutional Trading of Zoetis

Several large investors have recently added to or reduced their stakes in ZTS. Secured Retirement Advisors LLC bought a new position in Zoetis in the 4th quarter worth $844,000. Sigma Planning Corp increased its position in shares of Zoetis by 3.8% during the fourth quarter. Sigma Planning Corp now owns 3,401 shares of the company’s stock valued at $424,000 after buying an additional 124 shares during the period. Laurel Wealth Advisors LLC bought a new position in Zoetis in the fourth quarter worth about $50,000. Verity Asset Management Inc. lifted its holdings in Zoetis by 11.5% in the fourth quarter. Verity Asset Management Inc. now owns 2,634 shares of the company’s stock worth $331,000 after buying an additional 271 shares during the period. Finally, Bogart Wealth LLC boosted its position in Zoetis by 48.1% during the 4th quarter. Bogart Wealth LLC now owns 351 shares of the company’s stock valued at $44,000 after acquiring an additional 114 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $124.79 on Friday. The firm has a market cap of $54.99 billion, a P/E ratio of 21.01, a P/E/G ratio of 2.10 and a beta of 0.97. The firm’s fifty day moving average is $124.08 and its 200 day moving average is $137.26. Zoetis has a 52 week low of $115.25 and a 52 week high of $177.40. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company’s revenue was up .5% on a year-over-year basis. During the same period in the prior year, the business posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is presently 35.69%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.